Connect with us

Media OutReach

New Report Calls for Collective Action to Combat Asia’s Growing Antimicrobial Resistance Threat

Published

on

  • The Centre for Impact Investing and Practices and the World Economic Forum’s GAEA (Giving to Amplify Earth Action) initiative, supported by the Philanthropy Asia Alliance, have released a study urging cross-sector investment to tackle antimicrobial resistance (AMR) in Asia.
  • AMR could cost Asia up to US$700 billion by 2050 and surpass cancer as the world’s leading cause of death.
  • Report outlines four high-impact intervention areas – from education and prevention to surveillance and treatment – to guide funders and partners.

SINGAPORE – Media OutReach Newswire – 5 May 2025 – The Centre for Impact Investing and Practices (CIIP) and the World Economic Forum’s GAEA (Giving to Amplify Earth Action) initiative, supported by the Philanthropy Asia Alliance (PAA), today launched the report — Targeted Action and Financing the Fight Against Antimicrobial Resistance in Asia.

The report underscores the urgent threat of antimicrobial resistance (AMR) in Asia and outlines four key areas where cross-sector funders can drive meaningful impact. It draws on insights from 15 case studies and examples of funding mechanisms, and contributions from 26 organisations, including international organisations, corporations, philanthropic funders, public institutions, and solution providers.

Often called the silent pandemic, AMR was linked to 4.7 million deaths annually in 2021.[1] It is estimated to become the leading cause of death by 2050, claiming more than 8 million lives[2] and surpassing cancer[3]. Beyond human health, AMR threatens global food systems by reducing global livestock production and polluting waterways. Tackling this growing crisis requires a unified, whole-of-ecosystem approach.

“Antimicrobial resistance is a mounting crisis that threatens to reverse decades of medical progress, with Asia at the epicenter of this challenge. We have identified clear needs, but no single organisation can tackle this alone and substantial philanthropic and catalytic funding is required. It demands all actors — across sectors and borders — to step up, pool resources, and collaborate. Together, we hope that through active partnerships, we can build a future where effective treatments remain within everyone’s reach,” said Ms. Dawn Chan, Chief Executive Officer, CIIP.

“The Davos Compact on Antimicrobial Resistance (AMR), launched earlier in January this year, seeks to mobilise public-private-philanthropic, cross sectoral collaboration to reduce the global and increasing threat of AMR. This report builds on the Davos Compact, highlighting practical, high impact interventions where catalytic investments can help safeguard health and well-being, reducing risks and deaths associated with AMR,” said Ms. Gim Huay Neo, Managing Director, Member of the Managing Board, World Economic Forum.

Asia: A Crucible for the Multifaceted AMR Challenge

Globally, nearly one in five AMR-related deaths occur in children under five[4], and two in three in adults over 65[5]. However, Asia bears the brunt of the disease incidence, accounting for more than half of the 4.71 million deaths worldwide associated with AMR in 2021[6]. Rising temperatures and extreme weather events are accelerating bacterial growth and disease transmission, while disrupting healthcare and immunisation services – particularly in regions with inadequate healthcare infrastructure and sanitation. These climate-related pressures are also driving the increased use of antimicrobials in livestock and crops, contaminating freshwater sources and fuelling drug resistance.

In Asia Pacific alone, AMR-related costs are projected to reach up to US$700 billion by 2050, accounting for up to 1% of the region’s GDP[7]. However, timely investment in AMR solutions could generate US$10–15 billion in annual healthcare savings, and cut annual socio-economic costs by up to US$40 billion for Asia Pacific within the next decade.[8] Tackling AMR is essential for health security, as well as ensuring long-term economic resilience and sustainable development.

A Unified Approach to Antimicrobial Development and Use

Despite research advancements, market and policy gaps make it challenging to bring new drugs to patients as the costs involved in development and regulatory approval tend to outweigh the immediate returns upon product launch. A One Health approach — one that recognises the interconnectedness and interdependence across humans, animals, plants, and the wider environment — is essential to tackle AMR sustainably.

While new therapeutics such as drugs and vaccines can take 10 to 15 years to develop and launch to market[9] (a marathon), immediate and practical interventions (sprints) are needed to curb resistance today and pave the way for long-term solutions.

The report thus proposes interventions in four areas:

  • Sprint 1: Educate – Improving knowledge and behaviour by strengthening awareness of AMR among clinicians, patients, and farmers; emphasising the importance of avoiding the overuse or abuse of antimicrobials; as well as introducing strategies to prevent infections in the first place.
  • Sprint 2: Prevent – Strengthening health systems and services by boosting preventive measures such as improving diagnostic capabilities and investing in better water, sanitation, and hygiene (WASH) measures.
  • Sprint 3: Monitor – Enhancing regional surveillance, and data collection and sharing between actors, especially in lower-income countries.
  • Marathon: Treat – Investing in research and development for new antimicrobials, and increasing access to novel and essential medicines.

Financing AMR Solutions At Every Stage

Private funders, impact investors, and philanthropists have a vital role to play in closing critical gaps – particularly in late-stage drug development, where funding is scarce. By pooling resources, funders can help bring life-saving treatments to market, strengthen the antibiotic pipeline, and build more sustainable and widespread access to essential medicines.

“This report is a catalyst for deeper involvement from all sectors — philanthropic, public, and private. It highlights the scale of the AMR threat and the opportunity for collective action. We are encouraged by the ongoing work of organisations – including PAA members like the Gates Foundation, Wellcome Trust, and Novo Nordisk Foundation – in driving AMR research and greater access to affordable solutions. Now is the time for more partners to come together, pool resources, and support high-impact solutions that safeguard health and resilience across Asia and beyond,” said Mr. Shaun Seow, Chief Executive Officer, PAA.

The AMR threat demands urgent, coordinated, and sustained action across healthcare, agriculture, and food systems to protect communities in Asia.

Read the full report here: https://ciip.com.sg/knowledge-hub/research-insights/Details/targeted-action-and-financing-the-fight-against-antimicrobial-resistance-in-asia


[1] Naghavi, M., Vollset, S. E., Ikuta, K. S. et al. (2024). Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. The Lancet, Volume 404, Issue 10459, p1199-1226. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01867-1/fulltext

[2] Naghavi, M., Vollset, S. E., Ikuta, K. S. et al. (2024). Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. The Lancet, Volume 404, Issue 10459, p1199-1226. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01867-1/fulltext

[3] Gavi (2022). Antimicrobial resistance now causes more deaths than HIV/AIDS and malaria worldwide – new study. 20 January 2022. Available at: https://www.gavi.org/vaccineswork/antimicrobial-resistance-now-causes-more-deaths-hivaids-and-malaria-worldwide-new.

[4] Antimicrobial Resistance Collaborators. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet, Volume 399, Issue 10325, p629-655. https://www.google.com/url?q=https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext%23supplementary-material&sa=D&source=docs&ust=1744866648294504&usg=AOvVaw0fopMXnonRugpe_OJ7JhIx

[5] Naghavi, M., Vollset, S. E., Ikuta, K. S. et al. (2024). Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. The Lancet, Volume 404, Issue 10459, p1199-1226. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01867-1/fulltext

[6] Institute for Health Metrics and Evaluation (IHME). (2024). The Lancet: More than 39 million deaths from antibiotic-resistant infections estimated between now and 2050, suggests first global analysis. https://www.healthdata.org/news-events/newsroom/news-releases/lancet-more-39-million-deaths-antibiotic-resistant-infections.

[7] L.E.K. Consulting (2021) Asia-Pacific in the Eye of AMR Storm: Nurturing Innovation To Fight Antimicrobial Resistance. https://www.lek.com/sites/default/files/PDFs/Nurturing-Innovation-AMR-management.pdf?trk=article-ssr-frontend-pulse_little-text-block

[8] L.E.K. (2021). Asia-Pacific in the Eye of AMR Storm: Nurturing Innovation To Fight Antimicrobial Resistance. https://www.lek.com/sites/default/files/PDFs/Nurturing-Innovation-AMR-management.pdf

[9] Derep, M. (2022). What’s the average time to bring a drug to market in 2022? N-Side. https://lifesciences.n-side.com/blog/what-is-the-average-time-to-bring-a-drug-to-market-in-2022.

The issuer is solely responsible for the content of this announcement.

About the Centre for Impact Investing and Practices

The Centre for Impact Investing and Practices (CIIP) was established in 2022 as a non-profit entity by Temasek Trust to foster impact investing and practices in Asia and beyond by building and sharing knowledge, bringing together stakeholders in the community, and bringing about positive action that accelerates the adoption of impact investing principles and practices. CIIP is the anchor partner for the United Nation Development Programme’s Private Finance for the SDGs, providing Asia investors and businesses with clarity, insights and tools that support their contributions towards achieving the SDGs. Temasek and ABC Impact are CIIP’s strategic partners. For more information, please visit .

About GAEA (Giving to Amplify Earth Action)

To reach net zero, reverse nature loss and restore biodiversity by 2050, funding for equitable climate and nature transitions must be stepped up by more than $3 trillion annually. No actor can solve these issues alone; only together – through partnerships, elevated ambition and accelerated learning – can the most pressing problems facing the planet be solved. The World Economic Forum launched the GAEA (Giving to Amplify Earth Action) initiative to convene 4P – Public, Private and Philanthropic Partnerships – for climate and nature, activating systemic bold partnerships to improve the state of the world.

About Philanthropy Asia Alliance

Philanthropy Asia Alliance (PAA) is a Temasek Trust initiative dedicated to catalysing collaborative philanthropy in Asia through dynamic multi-sector partnerships. By harnessing collective strengths, PAA multiplies impact, accelerates positive change, and takes urgent action to address the pressing environmental and social challenges of our time. PAA’s flagship programme is the annual Philanthropy Asia Summit. For more information, visit .

Advertisement

Media OutReach

A First in the Asia-Pacific – Taiwan Leads the Launch of the Early Kidney Disease Annual Report, Opening a New Era in Advancing Kidney Care

Published

on

TAIPEI, TAIWAN – Media OutReach Newswire – 11 December 2025 – Taiwan’s chronic disease care is once again at the forefront internationally, taking new strides with the release of the Asia-Pacific’s first “Early Chronic Kidney Disease Annual Report,” jointly published by the Ministry of Health and Welfare, the National Health Research Institutes, and the Taiwan Society of Nephrology. This report not only comprehensively covers the information on various stages of chronic kidney disease but also provides timely and internationally relevant data that has garnered high attention from the Asia-Pacific medical community.

Domestic and international leaders gathered at the launch ceremony of the 2025 Early CKD Annual Report Press Conference, symbolizing the formal release of the first early kidney disease annual report in the Asia-Pacific region and showcasing Taiwan’s international leadership position in precise kidney care. From left to right are:

  • Yung-Ho Hsu, Secretary General of the Taiwan Society of Nephrology
  • Shang-Jyh Hwang, Honorary President of the Taiwan Society of Nephrology
  • Masaomi Nangaku, Immediate Past-President of the International Society of Nephrology
  • Marcello Tonelli, President of the International Society of Nephrology
  • Mai-Szu Wu, President of the Taiwan Society of Nephrology
  • Chung-Liang Shih, Minister of the Ministry of Health and Welfare
  • Ching-Fen Shen, Director General of the Health Promotion Administration, Ministry of Health and Welfare
  • Chih-Cheng Hsu, Professor at the National Health Research Institutes
  • Hyeong-Cheon Park, President Elect of the Asia Pacific Society of Nephrology
  • Rajnish Mehrotra, President of the International Society of Peritoneal Dialysis

The complete and immediate analysis aids in reversing the past trend where most patients were diagnosed at late stages and required dialysis, ushering in a new era of early detection and treatment. Minister of Health and Welfare, Chung-Liang Shih, stated at a press conference that this annual report serves as a new engine for promoting precise care, integrating complete data and risk classification indicators for Early CKD P4P(Pay for Performance) and Pre-ESRD P4P. This fills the gap in early kidney disease data and strengthens the quantitative basis for policy and clinical decision-making, facilitating early intervention and delaying disease progression. The goal is to achieve the Healthy Taiwan Policy target of reducing the standardized mortality rate for chronic diseases by one-third by 2030, and for Taiwan’s care model to become an example in the Asia-Pacific, establishing a sustainable and precise new framework for kidney care.

The early kidney disease annual report reveals several key trends. According to KDIGO risk classification, the proportion of high-risk and very high-risk patients in the P4P program has gradually decreased in recent years, reflecting a shift in treatment strategies toward early intervention and prevention. This trend not only highlights the medical team’s emphasis on the care of early-stage chronic kidney disease patients but also helps delay disease progression and reduce the incidence of later-stage complications. In terms of controlling the “three highs” (hyperglycemia, hypertension, and hyperlipidemia), data shows that approximately 80% of patients meet lipid targets and nearly 60% maintain stable blood sugar levels. However, only about 30% meet the target for blood pressure below 130/80 mmHg, indicating significant challenges remain in blood pressure control. The “three highs” are important risk factors for the progression and deterioration of chronic kidney disease, making it crucial to further improve control rates. The implementation of the P4P program has already shown preliminary results, and there are expectations for more immediate, comprehensive, and rigorous data collection and tracking, which will more fully demonstrate the long-term benefits of this care model.

Data-Driven: Taiwan’s First Early Kidney Disease Annual Report Fills Care Gaps

Professor Chih-Cheng Hsu from the National Health Research Institutes pointed out that past domestic kidney disease care has primarily focused on dialysis and end-stage disease, with limited understanding of early stages and delayed updates on data. This annual report breaks through traditional reporting frameworks and represents the first integration of complete data and risk classification indicators for Early CKD P4P and Pre-ESRD P4P. Utilizing big data for in-depth analysis, it outlines the disease progression and comorbidity trends of patients at different risk levels, successfully filling the long-term gap in early kidney disease care. He noted that grasping information on early stages of disease helps clinicians intervene earlier and delay deterioration while providing quantitative evidence for health policies to promote proactive and timely kidney care strategies, enhancing Taiwan’s international competitiveness in precise health governance.

Early CKD P4P and Pre-ESRD P4P are two phased quality-based reimbursement programs promoted by the National Health Insurance Administration, addressing key care needs for early chronic kidney disease and pre-dialysis patients, respectively. Early CKD P4P primarily targets patients in CKD stages 1-3a, aiding healthcare institutions in early identification of kidney deterioration risks through disease tracking and integrated care models, providing personalized management. Pre-ESRD P4P focuses on patients in CKD stages 3b, 4-5, enhancing control of complications, medication, and nutritional management while utilizing data feedback to support treatment decisions, aiming to delay dialysis and improve care efficiency. Both programs link the complete processes from early prevention to pre-dialysis intervention, contributing to improved overall CKD care quality and patient long-term prognosis.

Precise Kidney Care: Holistic and Continuous CKD Care as a Model for Chronic Disease

Taiwan centers its approach on “precise care,” continuously optimizing the integrated chronic kidney disease care system to implement policy blueprints in clinical practice. Director General of National Health Insurance Administration, Lian-Yu Chen, mentioned that Taiwan has progressively refined various measures, from educational programs for pre-end-stage renal disease patients to integrated care plans for early chronic kidney disease. The medical team can adjust personalized treatment strategies based on patient risk classification and clinical data, strengthening disease management and follow-up effectiveness for early-stage patients. She indicated that by integrating and providing feedback across units, care gaps could be minimized to ensure that patients receive consistent medical services across different levels of care. Director General of Health Promotion Administration, Ching-Fen Shen, remarked that grassroots health education and community health advocacy go hand in hand to enhance public awareness of kidney health. Years of efforts have significantly slowed the deterioration of early kidney disease progression, with patients participating in integrated care exhibiting a lower future risk of dialysis compared to those who do not participate, showing tangible effectiveness of the Taiwan model.

Policy Linkage and Sustainable Vision: Achieving the Healthy Taiwan Goals and Leading the New Landscape of Asia-Pacific

In response to the government’s “Healthy Taiwan” policy, Taiwan is implementing a preventive kidney care model based on the Early CKD P4P and Pre-ESRD P4P systems and the Early Kidney Disease Annual Report. President of the Taiwan Society of Nephrology, Mai-Szu Wu, stated that investing in early chronic kidney disease management not only contributes to health sustainability but also reduces waste of medical resources, achieving dual benefits of health outcomes and environmental sustainability, assisting the government in its goal to reduce chronic disease mortality by one-third by 2030.

During the Asia-Pacific Nephrology Conference (APCN) held in Taipei this year, the Asia-Pacific’s first Early Kidney Disease Annual Report was officially unveiled. President of the International Society of Nephrology, Marcello Tonelli, and Immediate Past-President , Masaomi Nangaku, along with the President Elect of the Asia Pacific Society of Nephrology Hyeong-Cheon Park and Honorary Secretary Sunita Bavanandan attended as witnesses, attracting experts from South Korea, Japan, Thailand, Malaysia, Australia, New Zealand, Singapore, Hong Kong, Mongolia, Indonesia, and the Philippines. Additionally, various important domestic academic societies, including the Taiwan Academy of Family Medicine, Taiwan Society of Cardiology, the Diabetes Association of the Republic of China (Taiwan), the Taiwan Association of Clinical Diabetes, and the Taiwan Medical Clinics Association also participated and supported the event. Minister Chung-Liang Shih expressed gratitude for the collective efforts and emphasized that this kidney annual report showcases Taiwan’s leading position in medical data integration and clinical evidence, hoping that real-time and comprehensive data analysis will once again showcase Taiwan’s precision care model to the international community, working together with other countries to create a new global framework for chronic kidney disease prevention and treatment.

Hashtag: #TaiwanSocietyofNephrology

The issuer is solely responsible for the content of this announcement.

Continue Reading

Media OutReach

The Government of Angola Launches an International Public Tender for the Management of the Namibe Corridor

Published

on

LUANDA, ANGOLA – EQS Newswire – 12 December 2025 – The Ministry of Transport of The Republic of Angola (www.MinTrans.gov.ao) has today launched, 5th December, the Public Tender for the Concession of the Right to Operate, Manage and Maintain the Namibe Corridor. Interested entities may submit their proposals until 4 May 2026.

The concession, with an initial duration of 30 years, extendable up to 50 years, covers the operation, management, maintenance and preservation of the Moçâmedes–Menongue Railway Line, including rolling stock, associated infrastructure, workshops and the training centre. It further encompasses the possibility of designing and constructing new sections, extensions and branch lines, as well as railway connections to the Republic of Namibia and, at a later stage, to the Republic of Zambia.

The Secretary of State for Land Transport, Jorge Bengue, noted at the launch event that the process constitutes a strategic opportunity for international operators with a proven track record in the railway sector. “The Namibe Corridor has the potential to strengthen Angola’s role as a regional logistics platform, enhance supply chains, foster new investments, and increase the competitiveness of exports. We anticipate a dynamic tender process with strong participation from established industry operators,” he stated.

Jorge Bengue further emphasised that Angola has carried out structural reforms in recent years that have strengthened legal certainty and created a more competitive business environment. The success of the concession of the Lobito Corridor has demonstrated the country’s capacity to implement partnership models that stimulate private investment and accelerate the modernization of transport infrastructure.

Individual companies or consortiums of competitors with proven experience in the management of railway infrastructure and freight operations are eligible to apply. The detailed technical and financial requirements are set out in the tender documents, which are available for a fee of USD 20,000, or the equivalent in kwanzas at the exchange rate of the National Bank of Angola at the time of the transaction.

The Namibe Corridor encompasses the Moçâmedes Railway, with a total length of 855 km, and the Port of Namibe, forming a strategic logistics axis for the export of minerals, ornamental stones, agricultural products, and other goods. The infrastructure allows for a theoretical capacity of up to 5 million tonnes per year, serving as a connection point for landlocked countries in the region, in coordination with the Lobito and Walvis Bay corridors.

This corridor also contributes to tourism development and regional integration, strengthening Angola’s position in Atlantic–Indian trade routes and consolidating the country as a significant commercial hub within the African context.

Distributed by APO Group on behalf of Ministry of Transport of Angola.

Download Image: https://apo-opa.co/48GQeet
Caption: The official launch of the Public Tender, presided over by the Secretary of State for Land Transport, Jorge Bengue

The issuer is solely responsible for the content of this announcement.

Continue Reading

Media OutReach

VinFast VF 8 – Crafted for high-expectation markets in the GCC

Published

on

Premium design meets industry-leading warranty and long-term support

DUBAI, UAE – Media OutReach Newswire – 12 December 2025 – The Middle East’s electric vehicle market is still developing but advancing quickly. In the Gulf Cooperation Council (GCC) region, EV sales penetration doubled from about 2 per cent to roughly 4 per cent in just one year, placing the region among the fastest-growing EV markets globally. 91% of battery-electric vehicle owners here say they plan to buy another EV, above the global average of 87%.

Amid that backdrop, buyers are seeking vehicles that match or exceed the space, performance, and refinement expected from premium SUVs. VinFast VF 8 arrives as a direct response to these elevated expectations, combining sophisticated design, robust capability, and a comprehensive ownership framework built around long-term confidence.

The VF 8 is shaped by VinFast’s “Dynamic Balance” design philosophy, a deliberate interplay between flowing curves and precise, angular lines that creates a sense of energy and visual structure without sacrificing harmony. This design language feels both contemporary and enduring. The result is a vehicle that projects presence without aggression, offering an aesthetic that balances boldness with sophistication, qualities that resonate with Middle Eastern consumers who view their vehicles as reflections of personal standards.

Under the sculpted exterior lies engineering tuned for high-demand regional driving. The VF 8 Plus variant delivers all-wheel drive with up to 402 horsepower and 620 Nm of torque, accelerating from 0 to 100 kph in under 5.5 seconds. This translates to confident overtaking on high-speed highways, assured merging in dense urban traffic, and the capability to handle extended cruising. Range reaches up to 493 km (NEDC) in the Eco configuration, a practical threshold aligned with intercity travel patterns across the region.

The 15.6-inch infotainment display provides intuitive access to navigation and vehicle settings. Crucially for the region, dual-zone climate control paired with ventilated seats are essential features designed to maintain cabin comfort even during peak heat.

The VF 8 integrates a comprehensive suite of smart systems designed to reduce driver workload. Traffic Jam Assist manages stop-and-go driving in congested environments, easing the fatigue of gridlock. Highway Assist supports sustained motorway cruising, helping drivers maintain lane position during long-distance travel. These systems work together to create a driving experience that feels more secure and less demanding.

Where the VF 8 truly distinguishes itself is in VinFast’s approach to long-term ownership. Addressing anxieties around battery longevity and service maturity, VinFast offers what may be the industry’s most comprehensive warranty structure. The VF 8 comes with a 10-year/200,000-km vehicle warranty and a 10-year unlimited-kilometer battery warranty, and 5-year/100,000-km of free service, eliminating one of the primary concerns of electric vehicle ownership. It’s also supported by practical service infrastructure: mobile service capabilities bring maintenance to customers’ locations, while 24/7 roadside assistance ensures support is available whenever needed.

The VF 8 represents VinFast’s understanding that success in sophisticated markets like the GCC requires vehicles that genuinely align with how people live, drive, and make long-term decisions. For Middle Eastern buyers navigating the transition to electric mobility, the VF 8 offers confidence in all aspects: design, performance, comfort, and warranty support. From the first drive to years down the road, it’s an electric vehicle crafted to deliver peace of mind alongside capability.

Hashtag: #VinFast

The issuer is solely responsible for the content of this announcement.

Continue Reading

Trending